Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Prof Sandra Swain spoke to ecancer at the BGICC 2020 conference in Cairo, Egypt about metastatic HER2 breast cancer.
After reminding us of the results of the CLEOPATRA trial, she also outlines the excellent results from SABCS concerning trastuzumab deruxtecan.
Following this, Prof Swain outlines the HER2CLIMB trial which looks at patients with brain metastases.
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Multiple myeloma In Rwanda: The need for further research
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Hormonal receptor positive breast cancer adjuvant and metastatic indications
EAU 2024: Bladder cancer latest
Relapsed refractory multiple myeloma
Updates on triple-negative breast cancer and immunotherapy
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Neo-adjuvant therapy for different cancers in the Philippines